ru 24926 has been researched along with 1-methyl-3-isobutylxanthine in 1 studies
Studies (ru 24926) | Trials (ru 24926) | Recent Studies (post-2010) (ru 24926) | Studies (1-methyl-3-isobutylxanthine) | Trials (1-methyl-3-isobutylxanthine) | Recent Studies (post-2010) (1-methyl-3-isobutylxanthine) |
---|---|---|---|---|---|
30 | 0 | 0 | 5,148 | 5 | 279 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kelly, E; Nahorski, SR | 1 |
1 other study(ies) available for ru 24926 and 1-methyl-3-isobutylxanthine
Article | Year |
---|---|
Specific inhibition of dopamine D-1-mediated cyclic AMP formation by dopamine D-2, muscarinic cholinergic, and opiate receptor stimulation in rat striatal slices.
Topics: 1-Methyl-3-isobutylxanthine; 2-Chloroadenosine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine; Alprostadil; Animals; Benzazepines; Carbachol; Cholera Toxin; Corpus Striatum; Cyclic AMP; Isoproterenol; Morphine; Phenethylamines; Rats; Receptors, Cholinergic; Receptors, Dopamine; Receptors, Muscarinic; Receptors, Opioid; Vasoactive Intestinal Peptide | 1986 |